Public Health and Economic Impact
To assess the impact and cost effectiveness of spatial repellents, AEGIS partners will complete the following:
- Conduct modeling using project data to estimate cost per person protected to impact beyond the period of performance. The projected public health and economic impact on the number of cases averted across all ages for the trials are intended to inform the probability of adoption of spatial repellents into national programs.
- Address issues of cost of implementation by evaluating efficacy in relation to coverage using varied delivery systems.
- Monitor the cost of manufacturing for affordable pricing and incentivize the production of next in class spatial repellents ensuring options for procurement by donor agencies and countries.
- Mosquito ShieldTM will be registered in malaria endemic countries with reported high malaria incidence, prioritizing registration based on National Malaria Control Programs, implementation partners, and existing infrastructure.
Evidence will be disseminated to key stakeholders like manufacturers, donors, and implementers at convened meetings at the global, regional, and/or local level as well as presented to public through scientific meetings and/or peer-reviewed publications. The evidence will encourage competition and help create downward pressure on prices and therefore increase equitable access to spatial repellents filling the historic coverage gap resulting from an inability to reach underserved populations.
Project Lead: University of Notre Dame
This project is made possible thanks to Unitaid funding and support. Unitaid is a global health agency engaged in finding innovative solutions to prevent, diagnose, and treat diseases more quickly, effectively, and for affordable prices, in low- and middle-income countries. Unitaid’s work includes funding initiatives to address major diseases such as HIV/AIDS, malaria, and tuberculosis, as well as HIV co-infections and co-morbidities such as cervical cancer and hepatitis C, and cross-cutting areas, such as fever management. Unitaid is now applying its expertise to address challenges in advancing new therapies and diagnostics for the COVID-19 pandemic, serving as a key member of the Access to COVID Tools Accelerator. Unitaid is hosted by the World Health Organization.